Johnson & Johnson (JNJ) ends mid-stage eczema study after missing efficacy bar. The drug JNJ-5939 was well-tolerated but did not meet efficacy targets. JNJ remains committed to developing treatments for atopic dermatitis. Drug price negotiations in the US pose challenges. JNJ stands out for income-focused investors with a 63-year dividend increase streak.

Johnson & Johnson (JNJ) included in best pharma dividend stocks to buy in 2026. The company ended a mid-stage study of an experimental drug for atopic dermatitis. JNJ remains committed to developing new treatments for the condition. Despite challenges in drug pricing negotiations, JNJ’s dividend program remains reliable for income-focused investors.

Read more at Yahoo Finance: Johnson & Johnson (JNJ) Ends Mid-Stage Eczema Study After Missing Efficacy Bar